Key Highlights
- N-Power Medicine partners with Merck to expand oncology clinical trials.
- Innovative platform combines technology, AI, and research staff for efficient clinical workflows.
- Collaboration aims to broaden clinical research access for oncologists and patients.
- Series B funding round raises $72 million to support network expansion.
Source: Business Wire
Notable Quotes
- “We are proud to collaborate with Merck, a company that is leading innovation in the clinical development process and the acceleration of transformative medicines to people living with cancer.” — Mark Lee, M.D., Ph.D, Co-Founder and Chief Executive Officer at N-Power
- “This provides the opportunity to foster critically-needed innovation in the cancer care ecosystem with the potential to benefit patients in urgent need of new therapies.” — Marjorie Green, M.D., Senior Vice President, Head of Oncology Clinical Development at Merck
SoHC's Take
N-Power Medicine’s collaboration with Merck represents a significant advancement in the oncology clinical trial landscape. By integrating advanced technology, AI, and specialized research staff into everyday patient care, N-Power Medicine is streamlining the clinical research process. This partnership not only increases access to clinical trials for more patients but also ensures that oncologists can participate more actively in the research process. With substantial funding from the recent Series B round, N-Power Medicine is well-positioned to expand its innovative network and bring life-saving therapies to cancer patients more efficiently. This collaboration underscores the critical need for inclusive and accessible clinical research in oncology, setting a new standard for how trials can be conducted in the future.
